Urogesic Blue (Methenamine / Sodium Phosphate, Monobasic / Methylene Blue / Hyoscyamine Sulfate) - Summary

UROGESIC BLUE SUMMARY

Each tablet contains:

	Methenamine, USP	81.6 mg
	Monobasic Sodium Phosphate, USP	40.8 mg
	Methylene Blue, USP	10.8 mg
	Hyoscyamine Sulfate, USP	0.12 mg

UROGESIC-BLUE™ is indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as hypermotility which accompany lower urinary tract infections and as antispasmodic. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures.

See all Urogesic Blue indications & dosage >>

NEWS HIGHLIGHTS

Clinical Trials Related to Urogesic Blue (Methenamine / Sodium Cation / Methylene Blue / Hyoscyamine)

Phenazopyridine for Confirmation of Ureteral Patency [Recruiting]
In this prospective, randomized trial subjects will be randomized to receive phenazopyridine or no medication prior to pelvic reconstructive procedures that use cystoscopy to confirm ureteral patency intraoperatively.

Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg vs. Placebo [Completed]
This study will evaluate the safety and efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as a short term analgesic treatment for the primary symptoms of pain or burning when passing urine associated with uncomplicated urinary tract infections (uUTI)

Bioequivalence of Phenazopyridine HCl in Healthy Volunteers [Active, not recruiting]

Study to Assess the Efficacy and Safety of "P�lulas de Lussen�" Compared to the Pyridium� in the Symptomatic Control of Dysuria [Not yet recruiting]
Clinical Study, prospective, comparative, randomized, double-dummy entry with random from a total of 80 patients, 40 patients will receive the test medication (Pílulas de Lussen®) plus placebo and 40 patients will receive the comparative (Pyridium®) plus placebo.

Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI) [Completed]
The primary objective is to evaluate the safety and efficacy of Phenazopyridine HCl Tablets, USP 200 mg as a short term analgesic treatment of pain upon urination associated with Uncomplicated Urinary Tract Infections (uUTI). The secondary exploratory objective is to evaluate safety and efficacy of Phenazopyridine HCl Tablets, USP 200 mg as a short term analgesic treatment of burning upon urination associated with uUTI.

more trials >>